Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | BTK | Q06187 | 1/20 | 0.52 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 13/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21232389 | 1.00 | KMT2A (0.53) | KMT2AL3MBTL1BTKKDM1AMAOB | |
| SCHEMBL21311673 | 0.86 | KMT2A (0.51) | KMT2AL3MBTL1BTKKDM1AMAOB | |
| SCHEMBL20106544 | 0.86 | KMT2A (0.53) | KMT2AL3MBTL1BTKKDM1AMAOB | |
| SCHEMBL21232390 | 0.85 | KMT2A (0.52) | KMT2AL3MBTL1BTKKDM1AMAOB | |
| SCHEMBL20106566 | 0.85 | KMT2A (0.52) | KMT2AL3MBTL1BTKKDM1AMAOB | |
| SCHEMBL21232478 | 0.83 | BTK (0.60) | KMT2AL3MBTL1BTKKDM1AMAOB | |
| SCHEMBL21232399 | 0.83 | BTK (0.60) | KMT2AL3MBTL1BTKKDM1AMAOB | |
| SCHEMBL21221592 | 0.81 | TRPV1 (0.47) | KMT2ATRPV1 | |
| SCHEMBL21232504 | 0.80 | BTK (0.53) | KMT2AL3MBTL1BTKKDM1AMAOB | |
| SCHEMBL21232484 | 0.80 | BTK (0.53) | KMT2AL3MBTL1BTKKDM1AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10759743-B2 | Pd-catalyzed γ-C(sp3)-H arylation / heteroarylation of free amines | THE SCRIPPS RESEARCH INSTITUTE (US) | 2020-09-01 | — | — | US | disclosed |
| US-20190241508-A1 | PD-CATALYZED GAMMA-C(SP3)-H ARYLATION / HETEROARYLATION OF FREE AMINES | THE SCRIPPS RESEARCH INSTITUTE | 2019-08-08 | — | — | US | disclosed |
| WO-2018080897-A1 | PD-CATALYZED γ-C(SP3)-H ARYLATION / HETEROARYLATION OF FREE AMINES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2018-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10759743-B2 | Pd-catalyzed γ-C(sp3)-H arylation / heteroarylation of free amines | DBH, GRIA3, H1-3 | KMT2A 940/4885L3MBTL1 3167/4885BTK 4852/4885 |
| US-20190241508-A1 | PD-CATALYZED GAMMA-C(SP3)-H ARYLATION / HETEROARYLATION OF FREE AMINES | DBH, SNCA, H1-3 | KMT2A 975/4885L3MBTL1 3008/4885BTK 4855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.